Company Executives

Management Team

From the proxy statement filed May 27, 2026

Officer	Age	In this role	Joined	Pay
Sam Lee Co-Chief Executive Officer, President	66	Not stated	Not stated	Not reported
James J. Martin Co-Chief Executive Officer, Chief Financial Officer	59	Not stated	Not stated	Not reported
James Sapirstein Chief Executive Officer Title from the Form 4 dated Jun 3, 2026	Not stated	Not stated	Not stated	Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed May 27, 2026

Directors

serving now

Independent

Not stated

the proxy does not say

Average tenure

7.6 years

from year joined

CEO also chairs the board

Roger Kornberg

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Roger Kornberg Board chair	79	2020 6 years	Not stated	None stated	Xenetic Biosciences, Inc. (Nasdaq:XBIO)	$100,000
Phillip Frost	89	2014 12 years	Not stated	None stated	OPKO Health, Inc. (Nasdaq:OPK)	Not stated
Fred Hassan	80	2023 3 years	Not stated	None stated	EyePoint Pharmaceuticals, Precigen Inc. (Nasdaq: PGEN), BridgeBio Pharma, Inc. (Nasdaq: BBIO)	Not stated
Richard C. Pfenniger, Jr.	70	2021 5 years	Not stated	None stated	OPKO Health, Inc.	Not stated
Steven Rubin	65	2014 12 years	Not stated	None stated	Red Violet, Inc. (Nasdaq:RDVT)	Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed May 27, 2026

limited liability company controlled by Dr. Phillip Frost

controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company

$62,000 and $63,000

years ended December 31, 2025 and 2024

Three-year lease extension entered into August 14, 2024; Company paid a $4,000 lease deposit on the original agreement and total rent and other expenses were paid under the lease.

With Company Open in proxy

Frost Gamma Investments Trust

a trust in which Phillip Frost, M.D., a director of the Company, is the trustee

$2,000,000

2023

Purchased 1,015,229 shares of common stock at $1.97 per share under a Securities Purchase Agreement dated April 4, 2023, a $2,000,000 investment.

With Company Open in proxy

Fred Hassan

appointed a director of the Company several weeks after purchasing shares

$2,000,000

2023

Purchased 1,015,229 shares of common stock at $1.97 per share under the April 4, 2023 Securities Purchase Agreement, a $2,000,000 investment.

With Company Open in proxy

Comments

Company Executives

Management Team

Board of Directors

Related-party transactions